Diabetic neuropathy: Scope of the syndrome

American Journal of Medicine

Volumn 107, Issue 2 SUPPL. 2, 1999, Pages 2-8

  Greene, Douglas A ^a   Stevens, Martin J ^a   Feldman, Eva L ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEUROPATHY; HUMAN; NEUROPATHY; PRIORITY JOURNAL; CRANIAL NERVE PARALYSIS; DISABILITY; DISEASE DURATION; FOOT ULCER; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; LEG AMPUTATION; MORTALITY; NERVE CONDUCTION; SENSORIMOTOR NEUROPATHY; SYNDROME; ANIMAL; CHRONIC DISEASE; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; PATHOPHYSIOLOGY; PREVALENCE; REVIEW;

ALDEHYDE REDUCTASE; ENZYME INHIBITOR; QUINAZOLINE DERIVATIVE; ZENARESTAT;

ALDEHYDE REDUCTASE; ANIMALS; CHRONIC DISEASE; CONTROLLED CLINICAL TRIALS; DIABETIC FOOT; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; ENZYME INHIBITORS; HUMANS; NEURAL CONDUCTION; PREVALENCE; QUINAZOLINES; SYNDROME;

EID: 0032841226     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(99)00007-8     Document Type: Conference Paper

References (50)

1. Pirart J. Diabetes mellitus and its degenerative complications a prospective study of 4,400 patients observed between 1947 and 1973 . Diabetes Care. 1:1978;168-188.
2. Thomas P.K., Tomlinson D.R. Diabetic and hypoglycemic neuropathy. Dyck P.J., Thomas P.K., Griffin J.W., Low P.A., Podulso J.F. Peripheral Neuropathy. 1993;1219-1250 WB Saunders, Philadelphia.
3. Thomas P.K. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 46:(suppl 2):1997;S54-S57.
4. Thomas P.K. Metabolic neuropathy. J R Coll Physicians Lond. 7:1973;154-160.
5. Greene D.A., Sima A.A.F., Pfeifer M.A., Albers J.W. Diabetic neuropathy. Annu Rev Med. 41:1990;303-317.
6. Anand P., Terenghi G., Warner G., et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med. 2:1996;703-707.
7. Boulton A.J.M., Armstrong W.D., Scarpello J.H.B., Ward J.D. The natural history of painful diabetic neuropathy - a 4-year study. Postgrad Med J. 59:1983;556-559.
8. Archer A.G., Watkins P.J., Thomas P.K., et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry. 46:1983;491-499.
9. Pourmand R. Diabetic neuropathy. Neurol Clin. 15:1997;569-576.
10. Stewart J.D. Diabetic truncal neuropathy topography of the sensory deficit . Ann Neurol. 25:1989;233-238.
11. Dyrberg T., Benn J., Christiansen J.S., et al. Prevalence of diabetic autonomic neuropathy measured by simple bedside tests. Diabetologia. 20:1981;190-194.
12. Edmonds M.E., Nicolaides K.H., Watkins P.J. Autonomic neuropathy and diabetic foot ulceration. Diabetic Med. 3:1986;56-59.
13. Sampson M.J., Wilson S., Karagiannis P., et al. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med. 75:1990;635-646.
14. Stevens M.J., Dayanikli F., Raffel D.M., et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol. 31:1998;1575-1584.
15. Feldman E.L., Stevens M.J., Greene D.A. Pathogenesis of diabetic neuropathy. Clin Neurosci. 4:1997;365-370.
16. Stevens M.J., Feldman E.L., Greene D.A. The aetiology of diabetic neuropathy the combined roles of metabolic and vascular defects . Diabet Med. 12:1995;566-579.
17. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
18. Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial. Ann Neurol. 38:1995;869-880.
19. Yancey P.H., Clark M.E., Hand S.C., et al. Living with water stress evolution of osmolyte systems . Science. 217:1982;1214-1222.
20. Burg M.B., Kador P.F. Sorbitol, osmoregulation, and the complications of diabetes. J Clin Invest. 81:1988;635-640.
21. Henry D.N., Del Monte M., Greene D.A., Killen P.D. Altered aldose reductase gene regulation in cultured human retinal pigment epithelial cells. J Clin Invest. 92:1993;617-623.
22. Nakanishi T., Burg M.B. Osmoregulatory fluxes of myo-inositol and betaine in renal cells. Am J Physiol. 257:1989;C964-C970.
23. Stevens M.J., Lattimer S.A., Kamijo M., et al. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia. 36:1993;608-614.
24. Greene D.A., Lattimer S.A. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation. J Clin Invest. 72:1983;1058-1063.
25. Greene D.A., Sima A.A., Stevens M.J., Feldman E.L., Lattimer S.A. Complications neuropathy, pathogenetic considerations . Diabetes Care. 15:1992;1902-1925.
26. Pop-Busui R., Van Huysen C., Bayer L., et al. Attenuation of nerve vascular and functional deficits by nerve taurine replacement in the streptozotocin-diabetic rat. Diabetes. 47:1998;A537. (Abstr.).
27. Greene D.A., Sima A.A., Stevens M.J., et al. Aldose reductase inhibitors an approach to the treatment of diabetic nerve damage . Diabetes Metab Rev. 9:1993;189-217.
28. Greene D.A., Arezzo J.C., Brown M.B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology. 53:1999;580-591.
29. Low P.A., Tuck R.R., Takeuchi M. Nerve microenvironment in diabetic neuropathy. Dyck P.J., Thomas P.K., Winegrad A.L., Porte D. Diabetic Neuropathy. 1987;266-278 WB Saunders, Philadelphia.
30. Dyck P.J., Lais A., Karnes J.L., et al. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol. 19:1986;425-439.
31. Tesfaye S., Harris N., Jakubowski J.J., et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy a novel technique of nerve photography and fluorescein angiography [see comments] . Diabetologia. 36:1993;1266-1274.
32. Theriault M., Dort J., Sutherland G., Zochodne D.W. Local human sural nerve blood flow in diabetic and other polyneuropathies. Brain. 120:1997;1131-1138.
33. Nagamatsu M., Nickander K.K., Schmelzer J.D., et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 18:1995;1160-1167.
34. Hunt J.V., Dean R.T., Wolff S.P. Hydroxyl radical production and autoxidative glycosylation glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing . Biochem J. 256:1988;205-212.
35. Hunt J.V., Bottoms M.A., Mitchinson M.J. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production . Biochem J. 291:1993;529-535.
36. Lal S., Szwergold B.S., Taylor A.H., et al. Metabolism of fructose-3-phosphate in the diabetic rat lens. Arch Biochem Biophys. 318:1995;191-199.
37. Cameron N.E., Cotter M.A., Archibald V., et al. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia. 37:1994;449-459.
38. Low P.A., Nickander K.K., Tritschler H.J. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes. 46:(suppl 2):1997;S38-S42.
39. Ziegler D., Hanefeld M., Ruhnau K.J., et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid a 3-week multicentre randomized controlled trial (ALADIN Study) . Diabetologia. 38:1995;1425-1433.
40. Hellweg R., Hartung H.D. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus a possible role for NGF in the pathogenesis of diabetic neuropathy . J Neurosci Res. 26:1990;258-267.
41. Hellweg R., Raivich G., Hartung H.D., et al. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol. 130:1994;24-30.
42. Jakobsen J., Brimijoin S., Skau K., et al. Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes. 30:1981;797-803.
43. Brewster W.J., Fernyhough P., Diemel L.T., et al. Diabetic neuropathy, nerve growth factor and other neurotrophic factors [see comments]. Trends Neurosci. 17:1994;321-325.
44. Apfel S.C., Arezzo J.C., Brownlee M., et al. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 634:1994;7-12.
45. Apfel S.C., Kessler J.A., Adornato B.T., et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology. 51:1998;695-702.
46. Pan Z., Sampath D., Jackson G., et al. Nerve growth factor and oxidative stress in the nervous system. Adv Exp Med Biol. 429:1997;173-193.
47. +toxicity and oxidative stress in neonatal animals. Brain Res. 713:1996;178-185.
48. Williams L.R. Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment. Cerebrovasc Brain Metab Rev. 7:1995;55-73.
49. Garrett N.E., Malcangio M., Dewhurst M., Tomlinson D.R. Alpha-lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neurosci Lett. 222:1997;191-194.
50. Levin ME, O'Neal LW, Bowker J, eds. The Diabetic Foot, 4th ed. St. Louis, MO: CV Mosby, 1988;33.